Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical Progression in Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - May 27, 2025 349 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a post-hoc analysis of the ENZAMET study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Pomalidomide Viatris January 17, 2024 ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology... June 19, 2026 New option to treat advanced oesophageal cancer approved for NHS in... August 11, 2021 Young Woman’s Breast Cancer Diagnosis Ends Up Saving Her Mom’s Life... September 27, 2021 Load more HOT NEWS EMA Recommends Extension of Indications for Pembrolizumab to Malignant Pleural Mesothelioma Fake Amazon Delivery Driver Attempts to Steal Elderly Woman’s Cancer Drugs Adding Pembrolizumab to Chemotherapy with or without Bevacizumab Improves Overall Survival... Lucky 13-A Male Breast Cancer Story
